Report Scope:
The scope of this report includes an overview of peanut allergy management in comparison with Palforzia.
The report discusses technological, regulatory, and economic trends that are affecting the market. It also explains the major drivers of Palforzia immunotherapy.
This report provides a brief explanation of peanut allergy disorder with regional prevalence rates; discusses the different types of diagnostic tests and their applicability in diagnosing various allergens; and provides an overview of the growing immunotherapy market.
This report organizes information from diverse sources into a cohesive package that includes:
- A section on diagnostic products such as skin prick tests, specific IgE tests, and oral food challenge tests.
- An overview section on guidelines for the prevention of peanut allergy.
- Specific chapters focus on unmet needs, economic burden, emerging therapies, and regulatory structure.
- A company profile section that provides background information on companies active in the diagnostic and treatment arenas is also included.
Report Includes:
- An overview of the global market for peanut allergy
- Analysis of current and future market dynamics of peanut allergy market and identification of key drivers, restraints and opportunities
- Coverage of disease background and epidemiology and discussion on disease burden of peanut allergy
- Discussion on technological, regulatory and competitive elements as well as economic trends affecting the future marketplace and pipeline analysis of new products
- Evaluation of current market trends, market size, market forecast and market share analysis of the key companies of the industry and their key market strategies
- Profiles of major players of the industry, including Beckman Coulter Inc., GlaxoSmithKline and Hitachi Chemical Diagnostics Inc.
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Scope of Report
- Methodology
- Information Sources
- Analyst's Credentials
- Related Reports
Chapter 2 Summary
Chapter 3 Overview
- Introduction to Peanut Allergy
- Etiology and Pathophysiology
- Etiology
- Pathophysiology
- Diagnosis of Peanut Allergy
- History
- Skin Prick Test (SPT)
- Specific IgE (sIgE)
- Component-Resolved Diagnosis (CRD)
- Oral Food Challenge
- The Basophil Activation Test
- Epidemiology
Chapter 4 Unmet Needs
- Current Unmet Needs in Managing Peanut Allergies
- What We Know
- Unmet Needs
- Emerging Treatments: Immunotherapies
- What We Know
- Unmet Needs
- Unintentional and Casual Exposures
- What We Know
- Unmet Needs
Chapter 5 The Economic Impact of Peanut Allergies
- Burden of Peanut Allergies
- Direct Medical and Indirect Costs
- Quality of Life
- Current and Future Management of Peanut Allergies: Implications for Managed Care
- Economic Analysis of Oral Immunotherapy
- Barriers to OIT
Chapter 6 Palforzia: Overview and Market Outlook
- Drug Overview
- Scientific Summary
- Mechanism of Action
- Therapeutic Trials on Safety and Efficacy
- Adverse Effects
- Dosage, Administration, and Cost
- Risk Evaluation and Mitigation Strategy
- Current Status of Palforzia
- Regulatory
- Commercialization
- Market Analysis
- Incidence of Peanut Allergy
- The Role of Parents
- The Role of Allergists
- The Role of Payers
- Large Addressable Market
- Sales Launch Curve
Chapter 7 Peanut Allergy Prevention Guidelines
- Australia
- U.S. and Canada
- Addendum Guideline 1
- Addendum Guideline 2
- Addendum Guideline 3
Chapter 8 Emerging Therapies
- Viaskin Peanut: DBV Technologies
- Product Description
- Clinical and Regulatory Activities
- CA002: Camallergy
- Product Description
- Clinical and Regulatory Activities
- PRT100: ProTA Therapeutics
- Product Description
- Clinical and Regulatory Activities
- Dupixent (Dupilumab): Regeneron
- Product Description
- Clinical and Regulatory Activities
Chapter 9 Regulatory Structure
- Regulations in U.S.
- New Drug Approval
- The FDA Modernization Act of 1997
- Fast Track Status
- Special Protocol Assessments
- New Surveillance and Safety Requirements
- Medicare
- Regulations in Europe
- Pricing and Reimbursement
- Regulations in Japan
Chapter 10 Company Profiles
- Aimmune Therapeutics Inc.
- Alere Inc.
- Allergan Pharmaceuticals
- Alk-Abello A/S
- Allergopharma
- Ani Biotech Oy
- Beckman Coulter/Danaher
- Diagnostic Automation/Cortez Diagnostics Inc.
- Glaxosmithkline
- Hitachi Chemical Diagnostics Inc.
- Jubilant Hollisterstier
- Laboratory Corp. Of America Holdings
- Lincoln Diagnostics Inc.
- Quest Diagnostics
- Siemens Healthcare
- Smartpractice Denmark
- Taro Pharmaceutical Industries
- Terumo Medical Corp.
List of Tables
Table 1: Target System Involvement in the Presentation of Peanut Allergy
Table 2: Characteristics of Peanut Allergens
Table 3: Estimated Prevalence of Peanut Allergy Cases in Eight Major Markets, Through 2025
Table 4: Summary of Unmet Needs in Peanut Allergy
Table 5: Direct Medical Costs of Childhood Food Allergy
Table 6: Out-of-Pocket Costs* of Childhood Food Allergy
Table 7: Summary of Addendum Guidelines for Prevention of Peanut Allergy
Table 8: Alere’s Product Portfolio
Table 9: Allergan’s Product Portfolio
Table 10: ALK-Abelló’s Product Portfolio
Table 11: Allergopharma's Product Portfolio
Table 12: Ani Biotech Oy’s Product Portfolio
Table 13: Beckman Coulter’s Product Portfolio
Table 14: Cortez Diagnostics’ Product Portfolio
Table 15: GlaxoSmithKline’s Product Portfolio
Table 16: Hitachi Chemical Diagnostics’ Product Portfolio
Table 17: Jubilant HollisterStier’s Product Portfolio
Table 18: LabCorp’s Product Portfolio
Table 19: Lincoln Diagnostics’ Product Portfolio
Table 20: Quest Diagnostics’ Product Portfolio
Table 21: Siemens Healthcare’s Product Portfolio
Table 22: SmartPractice Denmark’s Product Portfolio
Table 23: Terumo Medical’s Products Portfolio
List of Figures
Figure 1: Pathophysiology of Peanut Allergy
Figure 2: Claim Lines with Diagnoses of Peanut Allergy and Anaphylactic Reaction to Peanuts, by Age Group, 2007-2016
Samples
LOADING...
Executive Summary
The objective of this study is to provide an overview of the current and future market dynamics of the peanut allergy treatment market. This report explores the key drivers, management of peanut allergy, epidemiology, economic burden, and includes an overview of PALFORZIA, a new peanut allergen treatment. The key players of peanut allergy management are also discussed in the report.
This report highlights current and future market potential for Palforzia, with an emphasis on the epidemiological and economic burden of peanut allergy.
Companies Mentioned
- Aimmune Therapeutics Inc.
- Alere Inc.
- Alk-Abello A/S
- Allergan Pharmaceuticals
- Allergopharma
- Ani Biotech Oy
- Beckman Coulter/Danaher
- Camallergy
- DBV Technologies
- Diagnostic Automation/Cortez Diagnostics Inc.
- Glaxosmithkline
- Hitachi Chemical Diagnostics Inc.
- Jubilant Hollisterstier
- Laboratory Corp. Of America Holdings
- Lincoln Diagnostics Inc.
- ProTA Therapeutics
- Quest Diagnostics
- Regeneron
- Siemens Healthcare
- Smartpractice Denmark
- Taro Pharmaceutical Industries
- Terumo Medical Corp.
